Elecsys^® Anti-TSHR

Elecsys Anti-TSHR (TRAK) is a fully automated test for detection of autoantibodies to the TSH receptor

Clinical utility

• Detection or exclusion of Graves’ autoimmune hyperthyroidism and differentiation from disseminated autonomy of the thyroid gland¹
  
• Monitoring therapy and prediction of relapse¹
• Assessing the risk of developing fetal ­hyperthyroidism in the last trimester of pregnancy²

Improved efficiency

• Fully automated test for more workflow efficiency, allows for consolidation of tests required for differential diagnosis of ­thyroid diseases
  
• Rapid availability of Anti-TSHR results supports cost- and time-efficient differential diagnosis of thyroid diseases and ­early treatment
  

High quality results

• Advanced assay quality, based on proven and leading ECL technology
  
• Excellent precision across the entire ­measuring range (figure 1)
  
• High diagnostic value, based on high ­sensitivity paired with high specificity (figure 2³)
  

Figure 1: The functional sensitivity of Elecsys Anti-TSHR at approx. 0.9 IU/L is significantly below the cut-off (≥1.75 IU/L), allowing clear differentiation of pathological results.

Figure 2: The high sensitivity of 97% and high specificity of 99.5% of the Elecsys Anti-TSHR assay support clinical accuracy

The clinical study comprised:

• 436 samples from apparently healthy individuals
  
• 210 patients with thyroid diseases excluding Grave's disease
  
• 102 patients with untreated Grave’s disease
  

Using a cutoff of 1.75 IU/L a clinical sensitivity of 97% and a specificity of 99% was obtained.